Protein Kinase C Epsilon Type nPKC-Epsilon or EC 2.7.11.13-Pipeline Review, H1 2016

Protein Kinase C Epsilon Type nPKC-Epsilon or EC 2.7.11.13-Pipeline Review, H1 2016


  • Products Id :- GMDHC0077TDB
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Pipeline Review, H1 2016', provides in depth analysis on Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted pipeline therapeutics.

The report provides comprehensive information on the Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)

The report reviews Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Overview 6

Therapeutics Development 7

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Products under Development by Stage of Development 7

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Products under Development by Therapy Area 8

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Products under Development by Indication 9

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Products under Development by Companies 12

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Companies Involved in Therapeutics Development 20

Hadasit Medical Research Services & Development Ltd 20

VM Discovery, Inc. 21

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Drug Profiles 22

Bryostatin-1-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

DHACP-6-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecule to Activate Epsilon PKC for Ischemic Stroke-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecule to Activate PKC Epsilon for Neurology-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

VMD-1201-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

VMD-2202-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Dormant Projects 33

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Discontinued Products 34

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)-Featured News & Press Releases 35

Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model 35

Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer's Disease 35

Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer's Disease 36

Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer's Disease 36

Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference 37

Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease 37

Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C 38

Apr 16, 2015: Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies 39

Apr 09, 2015: Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome 39

Apr 06, 2015: Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease 40

Mar 30, 2015: Severe Alzheimer's Patient Responds to Bryostatin Treatment 41

Mar 17, 2015: Neurotrope Announces Positive Final Results from Its Phase 2a Safety Study for the Treatment of Alzheimer's Disease 42

Feb 24, 2015: Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer's Disease 42

Nov 20, 2014: Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease 43

Aug 18, 2014: Neurotrope's Approach to Treating Alzheimer's Disease Through Its Product Bryostatin-1, an Activator of Protein Kinase C Epsilon (PKCe), Supported by Blanchette Rockefeller Neurosciences Institute (BRNI) Publication, Identifying PKCe as a Biomarker of Alzheimer's 44

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Figures

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Top 10 Indication, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 11

Assessment by Monotherapy/Combination Products, H1 2016 14

Number of Products by Mechanism of Actions, H1 2016 15

Number of Products by Stage and Mechanism of Actions, H1 2016 15

Number of Products by Stage and Routes of Administration, H1 2016 17

Number of Products by Molecule Types, H1 2016 18

Number of Products by Stage and Molecule Type, H1 2016 18

List of Tables

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Indication, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Early Stage Products, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Products under Development by Companies, H1 2016 13

Assessment by Monotherapy/Combination Products, H1 2016 14

Number of Products by Stage and Mechanism of Action, H1 2016 16

Number of Products by Stage and Route of Administration, H1 2016 17

Number of Products by Stage and Molecule Type, H1 2016 19

Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016 20

Pipeline by VM Discovery, Inc., H1 2016 21

Dormant Projects, H1 2016 33

Discontinued Products, H1 2016 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Hadasit Medical Research Services & Development Ltd

VM Discovery, Inc.

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Therapeutic Products under Development, Key Players in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Therapeutics, Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Pipeline Overview, Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Pipeline, Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Pipeline Assessment

select a license

Single User License
USD 3500 INR 225225
Site License
USD 7000 INR 450450
Corporate User License
USD 10500 INR 675675

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com